All In Biotech

Drug Trial Radar · NCT04379050

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

130

Actual

Start

Jun 8, 2020

Primary completion

Apr 17, 2026

Study completion Apr 17, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to continue testing whether ABBV-951 is safe, effective, and tolerable in participants with Parkinson's disease after completion of the parent study M15-741. ABBV-951 is an investigational (unapproved) drug containing levodopa phosphate/carbidopa phosphate (LDP/CDP) given as infusion under the skin for the treatment of Parkinson's Disease. Participants who have successfully completed M15-741 study will immediately enter this study's treatment period to continue receiving ABBV-951. Adult participants with advanced PD will be enrolled. Approximately 130 adult participants will be enrolled in the study at approximately 65 sites worldwide. Participants will receive continuous subcutaneous infusion (CSCI) of ABBV-951 for 24 hours daily during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular clinic visits and have remote assessments completed via phone calls during the course of the study. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.

Conditions

  • Parkinson's Disease (PD)

Interventions

  • ABBV-951Drug

    Solution for continuous subcutaneous infusion (CSCI).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse Events (AE)Time frame: Up To Week 96
  2. Percentage Of Participants With Numeric Grade Equal To Or Higher Than 5 On The Infusion Site Evaluation ScaleTime frame: Up To Week 96
  3. Percentage Of Participants With Letter Grade Equal To Or Higher Than D On The Infusion Site Evaluation ScaleTime frame: Up To Week 96
  4. Change in Clinical Laboratory Test DataTime frame: Up To Week 96
  5. Change in Vital Signs MeasurementsTime frame: Up To Week 96
  6. Change From Baseline in Electrocardiograms (ECGs)Time frame: Up To Week 96

Locations

51 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - Main /ID# 215597

    Birmingham, Alabama

  • Banner Sun Health Research Institute /ID# 215579

    Sun City, Arizona

  • University of Colorado Hospital /ID# 215625

    Aurora, Colorado

  • Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 215412

    Boca Raton, Florida

  • Indiana Clinical Research Cent /ID# 216490

    Indianapolis, Indiana

  • Univ Kansas Med Ctr /ID# 215624

    Kansas City, Kansas

  • Washington University-School of Medicine /ID# 215472

    St Louis, Missouri

  • Dartmouth-Hitchcock Medical Center /ID# 216834

    Lebanon, New Hampshire

  • M3 Wake Research - Raleigh /ID# 215596

    Raleigh, North Carolina

  • Legacy Medical Group - Neurology /ID# 215536

    Portland, Oregon

  • Baylor College of Medicine /ID# 215401

    Houston, Texas

  • Central Texas Neurology Consul /ID# 217013

    Round Rock, Texas

  • Univ Texas HSC San Antonio /ID# 215400

    San Antonio, Texas

  • Booth Gardner Parkinson's Care Center /ID# 215535

    Kirkland, Washington

  • Inland Northwest Research /ID# 215533

    Spokane, Washington

  • Concord Repatriation General Hospital /ID# 215943

    Concord, New South Wales, Australia

  • Westmead Hospital /ID# 215941

    Westmead, New South Wales, Australia

  • Duplicate_Royal Adelaide Hospital /ID# 215940

    Adelaide, South Australia, Australia

  • The Alfred Hospital /ID# 215942

    Melbourne, Victoria, Australia

  • Perron Institute /ID# 215944

    Nedlands, Western Australia, Australia

  • Duplicate_Groupe Sante CHC - Clinique du MontLegia /ID# 215685

    Liège, Belgium

  • Universitair Ziekenhuis Leuven /ID# 215684

    Leuven, Vlaams-Brabant, Belgium

  • Duplicate_Algemeen Ziekenhuis Sint-Jan Brugge /ID# 215686

    Bruges, West-Vlaanderen, Belgium

  • University of Calgary /ID# 215369

    Calgary, Alberta, Canada

  • Clinique Neuro Levis /ID# 215371

    Lévis, Quebec, Canada

  • Bispebjerg and Frederiksberg Hospital /ID# 215391

    Copenhagen NV, Capital Region, Denmark

  • Aarhus Universitetshospital - Skejby /ID# 215392

    Aarhus, Central Jutland, Denmark

  • Odense University Hospital /ID# 215390

    Odense, Region Syddanmark, Denmark

  • Kliniken Beelitz GmbH /ID# 215403

    Beelitz-Heilstätten, Germany

  • Universitaetsklinikum Ulm /ID# 215405

    Ulm, Baden-Wurttemberg, Germany

  • curiositas ad sanum /ID# 215404

    Haag i.OB, Bavaria, Germany

  • IRCCS Centro Neurolesi Bonino Pulejo /ID# 215422

    Messina, Italy

  • Azienda Ospedale-Universita Padova /ID# 215421

    Padova, Italy

  • National Hospital Organization Asahikawa Medical Center /ID# 218762

    Asahikawa-shi, Hokkaido, Japan

  • Duplicate_Osaka University Hospital /ID# 217415

    Suita-shi, Osaka, Japan

  • National Center of Neurology and Psychiatry /ID# 218763

    Kodaira-shi, Tokyo, Japan

  • St. Antonius Ziekenhuis, Locatie Utrecht /ID# 215396

    Utrecht, Netherlands

  • Academician I.P. Pavlov First St. Petersburg State Medical University /ID# 218869

    Saint Petersburg, Sankt-Peterburg, Russia

  • City Clinical Hospital #40 /ID# 218870

    Sestroretsk, Sankt-Peterburg, Russia

  • Hospital Santa Creu i Sant Pau /ID# 215429

    Barcelona, Spain

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.